Brief: Virpax Pharmaceuticals Reports On FDA Pre-IND Response For NobrXiol
14/12/2022 14:35
Dec 14 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX PHARMACEUTICALS REPORTS ON FDA PRE-IND RESPONSE FOR
NOBRXIOL™ (FORMERLY VRP324)
Source text for Eikon: ID:nBw2sP00Ja
Further company coverage: VRPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study